Astrazeneca Pharma India Board of Directors

Get the latest insights into the leadership at Astrazeneca Pharma India. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Shilpa Divekar NirulaChairperson
Revathy AshokNon Executive Independent Director
Monica WidhaniNon Executive Independent Director
Hooi-Bien ChuahNon Executive Director
Praveen Rao AkkinepallyExecutive Director
Bhavana AgrawalWhole Time Director
Tanya SanishCompany Secretary and Compliance Officer

Astrazeneca Pharma India Share price

ASTRAZEN

8456.5

16.50 (0.20%)
NSE
BSE
Last updated on 23 Apr, 2026 | 15:31 IST
Today's High

8544.00

Today's Low

8416.00

52 Week Low

7551.50

52 Week High

10691.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Astrazeneca Pharma India FAQs

The board at Astrazeneca Pharma India consists of experienced professionals, including Shilpa Divekar Nirula, Revathy Ashok, and others, overseeing the company’s strategic and corporate governance.

Directors at Astrazeneca Pharma India are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Shilpa Divekar Nirula is the current chairman at Astrazeneca Pharma India.

Executive directors at Astrazeneca Pharma India are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Astrazeneca Pharma India adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Astrazeneca Pharma India, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost